US Congress Senate Bill 1801 (Prior Session Legislation)

---

Spectrum: Strong Partisan Bill (Democrat 15-1)
Status: Introduced on June 12 2019 - 25% progression, died in committee
Action: 2019-06-12 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Revises and expands various requirements relating to prescription-drug pricing and affordability. Specifically, the bill expands financial reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans and group health plans; modifies requirements for the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; limits the time frame that trade agreements are required to provide market exclusivity for biological products; establishes an innovation incentive fund for new or more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; revises certain time frames and conditions related to drug exclusivity; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings.

Affordable Medications Act

Sen. Tina Smith [D-MN]	Sen. Amy Klobuchar [D-MN]	Sen. Richard Blumenthal [D-CT]	Sen. Tom Udall [D-NM]
Sen. Sherrod Brown [D-OH]	Sen. Elizabeth Warren [D-MA]	Sen. Bernard Sanders [I-VT]	Sen. Margaret Hassan [D-NH]
Sen. Sheldon Whitehouse [D-RI]	Sen. Jeff Merkley [D-OR]	Sen. Jack Reed [D-RI]	Sen. Tammy Baldwin [D-WI]
Sen. Cory Booker [D-NJ]	Sen. Richard Durbin [D-IL]	Sen. Kirsten Gillibrand [D-NY]	Sen. Kamala Harris [D-CA]

Date	Chamber	Action
2019-06-12	Senate	Read twice and referred to the Committee on Finance.

HB447 (Related) 2019-01-25 - Referred to the Subcommittee on Health.
HB1093 (Related) 2019-02-07 - Referred to the Subcommittee on Health.
HB1506 (Related) 2019-04-08 - Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
SB73 (Related) 2019-01-10 - Read twice and referred to the Committee on Finance.
SB97 (Related) 2019-01-10 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
SB378 (Related) 2019-02-07 - Read twice and referred to the Committee on Finance.
SB1785 (Related) 2019-06-11 - Read twice and referred to the Committee on Finance.
SB64 (Related) 2019-01-09 - Read twice and referred to the Committee on the Judiciary.
HB1478 (Related) 2019-03-01 - Referred to the Subcommittee on Health.
HB8399 (Related) 2020-09-25 - Referred to the House Committee on Ways and Means.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/1801/all-info
Text	https://www.congress.gov/116/bills/s1801/BILLS-116s1801is.pdf